Deliberate buffy-coat transfusions and the risk of antibody formation.
Antibody formation was monitored after buffy-coat transfusions were given at weekly intervals for 9 weeks or a single injection of buffy-coat pooled from ten different donors was given. Among patients with no prior transfusion history, 7 patients given repeated transfusions did not develop warm B or T cytotoxins. Among 25 patients receiving pooled buffy-coat, only 1 patient (who had 3 prior pregnancies) developed warm B and T cytotoxins. In contrast, approximately one fourth of patients who had prior blood transfusions developed warm B and T cytotoxins with either repeated or pooled buffy-coat transfusions. We conclude that buffy-coat from 10 donors given weekly or as a single pooled injection does not produce warm B and T cytotoxins in nontransfused patients, but does function as a secondary stimulus in primed patients.
D000961:Antilymphocyte Serum / Q000145:classification; D001402:B-Lymphocytes / Q000276:immunology; D001803:Blood Transfusion / Q000379:methods*; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D006801:Humans; D007668:Kidney / Q000276:immunology; D016030:Kidney Transplantation; D017708:Leukocyte Transfusion; D008297:Male; D011247:Pregnancy; D012306:Risk; D013601:T-Lymphocytes / Q000276:immunology; D013997:Time Factors; D065227:Transfusion Reaction
D000961:Antilymphocyte Serum